Standout Papers
Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors
2015
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
2017
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
2014
Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
2015
Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
2014
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
2015
Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
2014
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
2018
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
2015
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy
2014
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
2015
Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation
2013
Cancer statistics, 2020
2020 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
2015
An Acquired and Endogenous Glycocalyx Forms a Bidirectional “Don’t Eat” and “Don’t Eat Me” Barrier to Phagocytosis
2020 StandoutNobel
Measurement of fatiguedetermining minimally important clinical differences
2002
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
2015
Phagocytosis checkpoints as new targets for cancer immunotherapy
2019
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
2014
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Linker Technologies for Antibody–Drug Conjugates
2013
Interpretation of Changes in Health-related Quality of Life
2003 Standout
Targeted therapy in rare cancers—adopting the orphans
2012
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
2012
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
2018
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
Nano based drug delivery systems: recent developments and future prospects
2018 Standout
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
2012
Delivery technologies for cancer immunotherapy
2019 Standout
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
2014 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
2018
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
2013
Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy
2015
The development of immunoconjugates for targeted cancer therapy
2014
Highly Stereoselective Biocatalytic Synthesis of Key Cyclopropane Intermediate to Ticagrelor
2016 StandoutNobel
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Emerging formats for next-generation antibody drug conjugates
2015
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
2015
Clinical targeting of the TNF and TNFR superfamilies
2013
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
The PI3K Pathway in Human Disease
2017 Standout
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Liquid Biopsies and Cancer Immunotherapy
2018
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
2014
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
Pain and Fatigue Management: Results of a Nursing Randomized Clinical Trial
2002
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Functional Roles of the IgM Fc Receptor in the Immune System
2019 StandoutNobel
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
2018
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Association Between Palliative Care and Patient and Caregiver Outcomes
2016 Standout
Acute Myeloid Leukemia
2015 Standout
Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy
2016
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
2019
Mechanisms of Resistance to Antibody–Drug Conjugates
2016
Integrative Nonpharmacologic Behavioral Interventions for the Management of Cancer-Related Fatigue
2007
Synthetic approaches to the 2011 new drugs
2013
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
FRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody–Drug Conjugates
2018
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
2011
Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
2014
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Chimeric Antigen Receptor Therapy
2018 Standout
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Cancer-Related Fatigue: The Scale of the Problem
2007
Antibody–drug conjugates
2013
Current Progress on aptamer-targeted Oligonucleotide Therapeutics
2013
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
2018
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
2016
Works of Robert Chen being referenced
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
2017
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2015
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Pembrolizumab-associated sarcoidosis
2016
Fatique Patterns Observed in Patients Receiving Chemotherapy and Radiotherapy
2000
Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells
2013
Brentuximab vedotin for the treatment of Hodgkin’s lymphoma
2015
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
2014
A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma
2015
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
2017
Targeting CD47 in Sézary syndrome with SIRPαFc
2019
Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma
2010
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
2012
Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma
2013
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
2014
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
2012
A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma
2015
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
2016